Restart Life Sciences Corp. NMLSF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 239.30K | 98.10K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 239.30K | 98.10K | -- | -- | -- |
| Cost of Revenue | 144.80K | 52.90K | -- | -- | -- |
| Gross Profit | 94.40K | 45.20K | -- | -- | -- |
| SG&A Expenses | 793.20K | 265.20K | 221.30K | 121.50K | 112.80K |
| Depreciation & Amortization | 6.70K | 2.90K | 300.00 | 300.00 | 300.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 942.00K | 324.70K | 221.60K | 121.90K | 113.10K |
| Operating Income | -702.80K | -226.60K | -221.60K | -121.90K | -113.10K |
| Income Before Tax | -734.50K | -237.70K | -112.80K | -153.20K | -147.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -734.50K | -237.70K | -112.80K | -153.20K | -147.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -734.50K | -237.70K | -112.80K | -153.20K | -147.10K |
| EBIT | -702.80K | -226.60K | -221.60K | -121.90K | -113.10K |
| EBITDA | -701.80K | -225.70K | -221.30K | -121.50K | -112.80K |
| EPS Basic | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | 0.00 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 60.75M | 56.51M | 39.29M | 35.89M | 33.59M |
| Average Diluted Shares Outstanding | 60.75M | 56.51M | 39.29M | 35.89M | 33.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |